Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) mHealth Randomized Controlled Hybrid Type I Effectiveness Implementation Trial
Overview:
A resurgent stimulant epidemic among men living with HIV could compromise the U.S. Ending the HIV Epidemic goals by interfering with HIV care engagement, adherence, and virologic suppression among men living with HIV. Prominent multi-level factors interfere with HIV virologic suppression for men living with HIV, particularly among those who use stimulants. This study is a randomized clinical trial to test a multi-component intervention to improve virologic suppression, adherence, and stimulant use among men living with HIV who use stimulants.
The intervention, known as reSTART, will combine an evidence-based positive affect mobile health (mHealth) intervention, a home-based urine point-of-care test for adherence self-monitoring, and motivational interviewing and messages. The goal of the reSTART intervention is to improve or maintain adherence to HIV medications and reduce stimulant use. By this high-impact study's end, the investigators will have identified the impact of a multi-component reSTART mHealth intervention using novel point-of-care adherence self-monitoring on HIV virologic suppression and stimulant use.
Study Type:
Quantitative
IRB Approved:
Yes
Target Audience:
Men living with HIV in the U.S. who report stimulant use and are prescribed ART with a tenofovir-based regimen.
Target Sample:
270
How to Apply:
Interested individuals can contact the research team at
restart@ucsf.edu. They will be asked to complete an online screening questionnaire, and if eligible, the research coordinator will reach out with information about the next steps.
Study Contact:
Matthew Spinelli
matthew.spinelli@ucsf.edu